Mechanistically, FASN binds to and upregulates HIF1α, inhibits ubiquitination, and promote nuclear translocation, thereby upregulating the downstream target SLC7A11 and subsequently reducing accumulation of lipid peroxidases, inhibiting HCC ferroptosis, and promoting sorafenib resistance in HCC. Here, SLC7A11 is linked to hepatocellular carcinoma.